Insmed (INSM) Other Non-Current Liabilities (2011 - 2026)
Insmed's (INSM) quarterly Other Non-Current Liabilities came in at $5.7 million in Q1 2026, down 96.96% year-on-year from $187.2 million in Q1 2025, and up 0.67% quarter-over-quarter from $5.6 million in Q4 2025.
Insmed (INSM) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Insmed's Other Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $5.7 million for Q1 2026.
- On a quarterly basis, Other Non-Current Liabilities fell 96.96% year-over-year to $5.7 million in Q1 2026; TTM through Mar 2026 was $5.7 million, a 96.96% decrease from a year earlier, with the FY2025 full-year figure at $5.6 million, down 96.66% from the prior year.
- Other Non-Current Liabilities improved to $5.7 million in Q1 2026 per INSM's latest filing, from $5.6 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $187.2 million in Q1 2025 and bottomed at $5.6 million in Q3 2025.
- The 5-year median for Other Non-Current Liabilities is $62.1 million (2022), against an average of $72.1 million.
- Across the five-year window, Other Non-Current Liabilities soared 2075.64% in 2024 and sank 96.96% in 2026, its largest moves.
- Year by year, Other Non-Current Liabilities stood at $58.1 million in 2022, then soared by 45.61% to $84.6 million in 2023, then soared by 99.65% to $168.9 million in 2024, then slumped by 96.66% to $5.6 million in 2025, then climbed by 0.67% to $5.7 million in 2026.
- Per Business Quant, the three latest INSM Other Non-Current Liabilities figures stand at $5.7 million (Q1 2026), $5.6 million (Q4 2025), and $5.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Insmed | 23.26 Bn | 22.03 Bn | 258.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.68 Mn |
| Dec 31, 2025 | 5.65 Mn |
| Sep 30, 2025 | 5.60 Mn |
| Jun 30, 2025 | 180.50 Mn |
| Mar 31, 2025 | 187.20 Mn |
| Dec 31, 2024 | 168.90 Mn |
| Jun 30, 2024 | 169.70 Mn |
| Mar 31, 2024 | 73.40 Mn |
| Dec 31, 2023 | 84.60 Mn |
| Sep 30, 2023 | 69.90 Mn |
| Jun 30, 2023 | 7.80 Mn |
| Mar 31, 2023 | 6.20 Mn |
| Dec 31, 2022 | 58.10 Mn |
| Sep 30, 2022 | 8.00 Mn |
| Jun 30, 2022 | 55.60 Mn |
| Mar 31, 2022 | 66.12 Mn |
| Dec 31, 2021 | 75.67 Mn |
| Sep 30, 2021 | 23.88 Mn |
| Jun 30, 2021 | 12.81 Mn |
| Mar 31, 2021 | 9.30 Mn |